KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Operating Expenses (2016 - 2025)

Amgen has reported Operating Expenses over the past 17 years, most recently at $7.1 billion for Q4 2025.

  • Quarterly results put Operating Expenses at $7.1 billion for Q4 2025, up 5.48% from a year ago — trailing twelve months through Dec 2025 was $27.7 billion (up 5.75% YoY), and the annual figure for FY2025 was $27.7 billion, up 5.75%.
  • Operating Expenses for Q4 2025 was $7.1 billion at Amgen, up from $7.0 billion in the prior quarter.
  • Over the last five years, Operating Expenses for AMGN hit a ceiling of $7.1 billion in Q4 2025 and a floor of $3.7 billion in Q1 2022.
  • Median Operating Expenses over the past 5 years was $5.3 billion (2021), compared with a mean of $5.5 billion.
  • Biggest five-year swings in Operating Expenses: fell 22.46% in 2022 and later surged 54.3% in 2024.
  • Amgen's Operating Expenses stood at $4.5 billion in 2021, then grew by 1.48% to $4.6 billion in 2022, then surged by 50.25% to $6.9 billion in 2023, then dropped by 2.17% to $6.8 billion in 2024, then increased by 5.48% to $7.1 billion in 2025.
  • The last three reported values for Operating Expenses were $7.1 billion (Q4 2025), $7.0 billion (Q3 2025), and $6.5 billion (Q2 2025) per Business Quant data.